Diagnostic and Therapeutic Challenges in Atypical Hemolytic Uremic Syndrome: A Case Report

Authors

  • Sofia Reis Serviço de Pediatria. Centro Hospitalar Tondela-Viseu. Viseu.
  • Daniela Ramos Hospital Pediátrico. Centro Hospitalar e Universitário de Coimbra. Coimbra.
  • Carolina Cordinhã Unidade de Nefrologia Pediátrica. Hospital Pediátrico de Coimbra. Centro Hospitalar e Universitário de Coimbra. Coimbra.
  • Clara Gomes Unidade de Nefrologia Pediátrica. Hospital Pediátrico de Coimbra. Centro Hospitalar e Universitário de Coimbra. Coimbra.

DOI:

https://doi.org/10.20344/amp.10021

Keywords:

Atypical Hemolytic Uremic Syndrome, Eculizumab

Abstract

The atypical hemolytic uremic syndrome comprises a thrombotic microangiopathy resulting from the complement alternate pathway hyperactivation. Its severity requires early diagnosis and treatment. The differential diagnosis includes typical hemolytic uremic syndrome (associated with Shiga toxin) and thrombotic thrombocytopenic purpura (associated with deficient activity of ADAMTS13). The only specific treatment currently available for atypical hemolytic uremic syndrome is eculizumab. We describe the case of a child with atypical hemolytic uremic syndrome diagnosed in the context of bloody diarrhea, complicated by neurological involvement that posed several diagnostic and therapeutic challenges.

Downloads

Download data is not yet available.

Published

2019-10-01

How to Cite

1.
Reis S, Ramos D, Cordinhã C, Gomes C. Diagnostic and Therapeutic Challenges in Atypical Hemolytic Uremic Syndrome: A Case Report. Acta Med Port [Internet]. 2019 Oct. 1 [cited 2024 Mar. 29];32(10):673-5. Available from: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10021

Issue

Section

Case Report